Venetoclax (VECLADX) 100mg Tablets | BCL-2 Inhibitor Generic for CLL/SLL & AML | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

مشاركة
Product description

Generic Information: VECLADX (Venetoclax)

VECLADX is a generic formulation of venetoclax, the world's first-in-class, orally bioavailable, selective inhibitor of the B-cell lymphoma-2 (BCL-2) protein. Venetoclax restores programmed cell death (apoptosis) in malignant cells and has become a cornerstone of treatment for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). VECLADX is manufactured by Bigbear Pharmaceutical (Lao) Co., Ltd. (Laos) under GMP-certified conditions and supplied worldwide by GIVE LIFE TIME LIMITED (GLT).

What Is VECLADX (Venetoclax) Used For?

VECLADX (venetoclax) is used for the treatment of adult patients with:

  • Chronic lymphocytic leukemia (CLL) — as fixed-duration therapy in combination regimens (e.g., with obinutuzumab or rituximab) or as monotherapy in relapsed/refractory disease, including 17p deletion / TP53-mutated CLL.
  • Small lymphocytic lymphoma (SLL).
  • Acute myeloid leukemia (AML) — in combination with azacitidine or low-dose cytarabine for newly diagnosed AML in patients ineligible for intensive induction chemotherapy.

In pivotal studies of originator venetoclax, fixed-duration combinations delivered superior progression-free survival and high rates of undetectable minimal residual disease (MRD) in CLL, and in AML venetoclax plus azacitidine achieved a complete response rate of 66.4% with median overall survival of 14.7 months in unfit patients.

How Does VECLADX (Venetoclax) Work?

Venetoclax selectively binds the anti-apoptotic BCL-2 protein that CLL cells and AML blasts rely on for survival. By displacing pro-apoptotic proteins such as BIM from BCL-2, it re-activates the apoptotic pathway, and the malignant cell self-destructs. This targeted mechanism delivers deep remissions with a manageable safety profile — and the generic formulation offers the same active molecule at a fraction of the originator price.

Indications

  • Chronic lymphocytic leukemia (CLL) — combination or monotherapy
  • Small lymphocytic lymphoma (SLL)
  • Acute myeloid leukemia (AML) — combination therapy in unfit patients
  • Active in high-risk 17p deletion / TP53-mutated disease

Dosage & Administration

Available strengths: 100mg × 112's.

For CLL, venetoclax is initiated with a 5-week once-daily ramp-up (20 mg → 50 mg → 100 mg → 200 mg → 400 mg) with mandatory tumor lysis syndrome (TLS) prophylaxis, hydration and laboratory monitoring, then continues at 400 mg once daily. For AML in combination with azacitidine, ramp up 100 mg → 200 mg → 400 mg over cycle 1 days 1–3, then 400 mg daily. Tablets are taken orally with food and water, swallowed whole, at the same time each day. Treatment must be initiated and supervised by an experienced hematologist/oncologist.

Side Effects

The most clinically important risk is tumor lysis syndrome (TLS) during initiation in high-tumour-burden patients. Common adverse reactions include neutropenia (with infection risk), diarrhoea, nausea, anaemia, thrombocytopenia, fatigue and cough. Strong CYP3A4 inhibitors/inducers require dose adjustment or avoidance. Venetoclax can cause fetal harm; effective contraception is required during and after treatment.

Storage

Store VECLADX tablets at controlled room temperature (20–25 °C) in the original packaging, protected from moisture. Keep out of reach of children. Ambient (non-cold-chain) shipping is suitable for oral tablets.

Why Choose the GLT?

  • Authentic, GMP-certified sourcing — Bigbear Pharmaceutical (Lao) Co., Ltd. manufactures VECLADX under GMP conditions with full batch documentation (CoA and batch traceability).
  • Affordable access — generic venetoclax offers a significantly lower cost per cycle than originator Venclexta/Venclyxto.
  • Same mechanism, same molecule — first-in-class BCL-2 inhibition delivering deep, MRD-negative remissions in CLL/SLL and AML.
  • Oral home-based treatment — fixed-duration tablet therapy, no infusion required.
  • Reliable supply by GLT — GIVE LIFE TIME LIMITED (Hong Kong) ships worldwide with CoA, CPP and batch traceability.

How to Order VECLADX (Venetoclax) from GLT?

  1. Contact us via WhatsApp +86 15234153837 or email [email protected] with the product name, specification and quantity.
  2. Receive a formal quotation, payment instructions and estimated delivery time.
  3. Complete payment via our secure payment channel (Hao Yi Lian / 好易联).
  4. Goods are dispatched with batch documentation; tracking provided until delivery.

We serve both licensed institutions (hospital procurement, pharmacies, importers) and individual patients. A valid prescription may be requested before dispatch.

FAQ

1. What strengths of VECLADX are available?

VECLADX is available as 100mg × 112's film-coated tablets. CLL therapy uses a 5-week ramp-up to the 400 mg daily target dose; AML combination therapy ramps to 400 mg daily.

2. Is generic venetoclax as effective as Venclexta?

Generic venetoclax contains the same active molecule at the same strength. VECLADX is manufactured under GMP-certified conditions, offering the same mechanism of action at a much lower cost.

3. Why is the ramp-up schedule so important?

The gradual 5-week dose ramp-up, hydration and lab monitoring keep tumor lysis syndrome (TLS) risk manageable during initiation and are mandatory safety measures.

4. How is VECLADX shipped internationally?

As an oral tablet, VECLADX ships via ambient temperature-controlled courier with full batch documentation. Typical delivery is 7–14 days depending on destination.

5. Can I order VECLADX for personal use?

GLT serves both institutions and individual patients. Individual buyers should hold a valid prescription and use this medicine under hematologist/oncologist supervision.

Related Oncology Products

Rizonib (كريزوتينيب) كبسولات 250 ملغ | بديل Xalkori الجنيس من DIL بنغلاديش لسرطان الرئة ALK+ | GLT

Rizonib 250 من Drug International Ltd (DIL)، تونغي غازيبور — بديل كريزوتينيب جنيس ميسور التكلفة...

لوسيافات (أفاترومبوباغ) 20ملغ*28 قرصاً | لوسيوس للأدوية (لاوس) | GLT

لوسيافات — أقراص أفاترومبوباغ 20ملغ (ماليات 23.6ملغ) مطلية بغشاء من لوسيوس للأدوية (لاوس) المحدودة، فيينتيان.

كيزيروي 科瑞泽 (أفاترومبوباغ) 20ملغ*10 أقراص | سيتشوان كيلون (الصين) | GLT

كيزيروي — أفاترومبوباغ المشتريات الوطنية من سيتشوان كيلون للأدوية، الشركة الصينية المتكاملة لتصنيع المادة الفعالة...

XinKePing 欣可平 (أفاترومبوباغ) 20 مجم × 10 أقراص | Nanjing Hencer الصين | GLT

XinKePing — أفاترومبوباغ من Nanjing Hencer Pharmaceutical (مجموعة Jemcare)، بتكامل رأسي بين المادة الفعالة والأقراص،...

بارينات (باريسيتينيب) 4ملغ | مثبط JAK1/JAK2 جنيس | ناتكو فارما المحدودة | GLT

باريسيتينيب جنيس (مثبط JAK1/JAK2) من ناتكو فارما المحدودة (الهند) — بديل ميسور التكلفة عن أولوميانت...

أورفورغليبرون (OriYo) أقراص 0.8–17.2 ملغ | دواء جينيريك بنغلاديشي فموي GLP-1 | GLT

جينيريك أورفورغليبرون من National Drug Co. (بنغلاديش)، نظام معايرة من 6 جرعات لإدارة الوزن

أورفورغليبرون (لوسيورفور) أقراص 0.8–17.2 ملغ | دواء جينيريك لاوسي فموي GLP-1 | GLT

جينيريك أورفورغليبرون من Lucius Pharmaceuticals (لاوس)، نظام معايرة من 6 جرعات لإدارة الوزن

أولوميانت (باريسيتينيب) أقراص 2ملغ/4ملغ | مثبط JAK1/JAK2 | إيلي ليلي (الولايات المتحدة) | GLT

مثبط انتقائي لـ JAK1/JAK2 من إيلي ليلي لعلاج التهاب المفاصل الروماتويدي والتهاب الجلد التأتبي والثعلبة...